The PD1/PDL1 reverse signaling can induce the expression of indoleamine 2,3-dioxygenase 1 (IDO1) in the tumor cells, which in turn causes phosphorylation of eIF2α with subsequent activation of ATF4 [17] and inhibition of IRF7 activity [18] in Treg, dendritic cells, myeloid-derived suppressor cells, and endothelial cells [27]. The gene discussed is IDO1; the disease is neoplasm.